Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0010200 (
cough
)
23,843
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
This controlled crossover study in twenty healthy volunteer subjects utilized the citric acid aerosol-induced
cough
response as a means to demonstrate the effectiveness of 25 mg of diphenhydramine as an antitussive. Entry was limited to only those subjects who manifested a consistent, quantitatively definable response to a 5% citric acid challenge. Subjects were initially dosed with either a placebo vehicle or 25 mg diphenhydramine in a 10 ml formulation. Following drug ingestion, subjects were challenged at 15, 30, 45, 60, 120, and 240 minutes. Three days later, subjects were administered the alternate treatment and rechallenged at the same time points.
Diphenhydramine
was effective at the earliest time point assessed, 15 minutes, and continued to be as effective over the entire 4-hour duration of the test period. For the placebo vehicle, the mean
cough
counts did not change significantly from baseline. Neither the putative soothing effect of a liquid formulation nor accommodation to the citric acid spray can account for all the early and consistently significant activity of diphenhydramine in suppressing the
cough
response. The early onset of activity of diphenhydramine may be due to its local anesthetic properties or may indicate that the dose of diphenhydramine required for effective antitussive activity is lower than that required for effective antihistaminic activity. These results require further corroboration in direct comparisons of various doses of diphenhydramine with positive controls in both this model and clinical
cough
counting models employing pathologic
cough
indices. A 25 mg dose of diphenhydramine appears to be effective as an antitussive agent.
...
PMID:Antitussive effects of diphenhydramine on the citric acid aerosol-induced cough response in humans. 186 43
The
cough
and emetic reflexes involve a synchronized firing of motor neurones involved in respiratory control. Tachykinin NK1 receptor antagonists and 5-HT1A receptor agonists are examples of centrally acting drugs that reduce
cough
and emesis. In the present studies, therefore, we examined the possibility that other classes of drugs known to reducing
cough
have anti-emetic properties to prevent emesis induced by diverse challenges. We examined the potential of codeine (1-10 mg/kg), baclofen (1-10 mg/kg), scopolamine (0.3-10 mg/kg), diphenhydramine (1-10 mg/kg), imperialine (1-30 mg/kg) and verticine (0.3-3 mg/kg) to inhibit emesis induced by nicotine (5 mg/kg, s.c.), copper sulphate (120 mg/kg, intragastric), and provocative motion (4 cm horizontal displacement, delivered at 1 Hz) in Suncus murinus (house musk shrew). Only codeine had broad inhibitory properties (P<0.05) to antagonize emesis induced by all challenges with ID50 values ranging from 1.2 to 2.3 mg/kg. Baclofen antagonized emesis induced by nicotine (maximum reduction was 44.9%, P<0.05) and motion (maximum reduction was 97.3%, P<0.01), but potentiated copper sulphate-induced emesis (maximum potentiation was 73.0%, P<0.05). Scopolamine antagonized copper sulphate-induced emesis (maximum reduction was 61.2%, P<0.05) and imperialine antagonized nicotine-induced emesis (maximum reduction was 30.2%, P<0.01), but verticine potentiated motion-induced emesis (maximum potentiation was 60.0%, P<0.05).
Diphenhydramine
did not significantly reduce emesis induced by any of the challenges (P>0.05). In conclusion, codeine has broad inhibitory anti-emetic actions but a known ability to reduce
coughing
does not necessarily predict broad inhibitory anti-emetic properties.
...
PMID:Action of anti-tussive drugs on the emetic reflex of Suncus murinus (house musk shrew). 1725 64
To evaluate the safety and efficacy of Linkus, Aminophylline with
Diphenhydramine
group and Acefyllin Piperazine with
Diphenhydramine
cough
syrup on children having
cough
and sleep difficulty associated with
cough
. To determine the effects of Linkus polyherbal syrup (group A) and compared with other parallel allopathic groups (Group B and C) for
cough
on children and associated sleep quality and improvement. 360 children having
cough
inducted in 3 different groups randomly selected. Three parallel groups were the part of the study. The first study group was the herbal syrup Linkus, second group of children were taking a syrup of multinational pharmaceutical industry having Aminophylline plus
Diphenhydramine
however the third group received another famous brand having Acefyllin Piperazine with
Diphenhydramine
. Informed assent and informed consent have taken from the study subjects and their parents. Subjects with acute
cough
were included in the study however the subjects with chronic cough considered to be excluded. Every group of individual in the study was informed about the investigational drugs provided. Ethnic groups, frequency of
cough
and diseases illness (<0.05) were determine on every group on the investigational syrup.
Cough
impact on child and its sleep of three different syrups (every group) were assessed on day1 and day 14(p<0.001) via a likert scale. For the evaluation of pain assessment Wong baker face scale were used and level of significance in each group (p<0.001). Significant results were observed in the Linkus Group as compared to the other parallel groups including Aminophylline plus
Diphenhydramine
and Acefyllin Piperazine with
Diphenhydramine
on day 14 (p<0.001). Side effects on group B and group C (Aminophylline with
Diphenhydramine
and Acefyllin Piperazine with
Diphenhydramine
) were almost similar in number however Linkus syrup has minimum side effects on study duration. Polyherbal syrup Linkus shows better results in treatment of
cough
including side effects as compare to the other parallel groups B and C (Aminophylline with
Diphenhydramine
and Acefyllin Piperazine with
Diphenhydramine
). For nocturnal sleep Linkus providing better results in
cough
and associated problems. Pain were significantly reduce on day 14 with the herbal Linkus syrup group A (<0.001). Group B and C found less effective with more side effects as compared to Linkus syrup. Poly herbal Linkus syrup could substantially improve the clinical effect and relieves coughs and benefit lung functions and better sleep facilitation.
...
PMID:Efficacy and safety of Linkus, Aminophylline diphenhydramine and acefyllin piperazine for the treatment of cough in children. 2738 95
The aim of the study is to determine the efficacy of polyherbal linkus with the other pharmaceutical marketed syrup having Acefyllin Piperazine,
Diphenhydramine
group and Aminophylline
Diphenhydramine
group on the basis of interquartile ranges on children. It was open label multi centric randomize control trial. The study was conducted on different private schools of East and West Malir, Karachi Pakistan with the special approval from the school's honors .informed consent and assents were taking before the enrollment of the study subjects .The study enrolled participants were 147 who evaluate on
cough
. Participants were divided into 3 interventional group according to the treatment regimen .One group of participant received Linkus Syrup however the 2nd group received Acefyllin Piperazine and 3rd group received Aminophylline
Diphenhydramine
group. The frequency of the
cough
on linkus syrup was considered to be achieved on the basis of interquartile relationship and impact has been observed on child and parent sleep and found significant (p <0.01).Poly herbal Linkus Syrup has the significant impact on
cough
frequency and associated problem on children and parent's sleep with minimum side effects (p<0.01) however the pharmacological treatments are considered to be more unwanted effects on human subjects.
...
PMID:An interquartile relationship between polyherbal extract based lozenges linkus a phase IV comparative randomised control trial. 2865 92
Introduction:
Diphenhydramine
(
DPH
) exposures in children may be the result of accidental unsupervised ingestions, caregiver error, and intentional misuse of
DPH
-containing
cough
and cold medications (CCM). We sought to understand the nature of pediatric ingestions of
DPH
, particularly the toxicity and outcome of a single product, single ingredient
DPH
(
DPH
-only) exposures, in order to derive ingredient-specific information about the clinical effects and course of such cases.
Methods:
As part of a U.S. multi-year safety surveillance program to assess the safety of over-the-counter (OTC) medications used in
cough
and cold preparations in children <12 years of age, an expert panel reviewed cases involving symptomatic adverse events potentially related to oral exposures to these medications. After individual review, the cases were categorized by causal relationship of the reported ingredients to the adverse event, exposure intent (therapeutic, non-therapeutic, unknown intent), and dose (therapeutic, supratherapeutic, or unknown). Following panel review, any disagreement on classification was discussed until a consensus was reached. The data were then analyzed with respect to descriptive findings.
Results:
The panel reviewed 6618 eligible cases and determined 2802 were at least potentially related to oral exposure to
DPH
. Of these, 2028 were
DPH
-only cases (39.1% of all cases judged at least potentially related to a
cough
and cold medication). The majority (79.5%) of
DPH
-only cases occurred in children 2 to <4 years of age and involved accidental unsupervised ingestions (74.7%). Liquid pediatric formulations were the most common (51.7%) products reported followed by solid pediatric formulations (24.0%). The most common adverse events were tachycardia (53.4%), hallucinations (46.5%), somnolence (34.7%), agitation (33.9%), and mydriasis (26.3%). Seizures occurred in only 5.5% of cases. Five (0.2%) deaths were reported; in the death cases, the
DPH
dose was judged supratherapeutic in one and unknown in the other four. Child abuse was reported in four of the five death cases and three of the five deaths were homicides.
Conclusions:
Exposures to
DPH
-only products were the most common type of exposure detected in our study of adverse events associated with CCM in children. The majority of the
DPH
-only cases were the result of accidental unsupervised ingestions. Most adverse events were relatively mild self-limited anticholinergic effects and few deaths occurred. Deaths involving
DPH
were often associated with child abuse or homicide. Interventions targeting the prevention of accidental unsupervised are likely to be impactful in preventing morbidity associated with
DPH
-only exposure.
...
PMID:Adverse events associated with diphenhydramine in children, 2008-2015. 3106 42